CSL Ozempic impact: Biotech giant says business shielded from big hits

  • 📰 FinancialReview
  • ⏱ Reading Time:
  • 45 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 21%
  • Publisher: 90%

Malaysia News News

Malaysia Malaysia Latest News,Malaysia Malaysia Headlines

The biotech giant also outlined an inverse Uber-style surge fee to reward people donating blood outside peak hours.

On Monday it outlined why it thinks its business is largely shielded.Biotechnology giant CSL argues an ageing population will help shield its business from any falloutweight loss, and potentially undermining its investment in therapies targeting kidney disease.

The plans were outlined at an investor day for CSL, a $116 billion company that is one of Australia’s big biotechnology growth stories, evolving from a government-owned enterprise established in 1916 to having 30,000 staff delivering products in more than 100 countries.with margins in blood collection centres under pressure and rivals planning to launch generic drugs against its iron deficiency product, Ferinject.

CSL head of research and development Bill Mezzanotte maintained the patients in the trial only represented a “small percentage of the overall dialysis patient population, which of course is only a small percentage of the business”. “However, offset by that, GLP-1s will do nothing for ageing,” he said. “And the overall population remains to continue to age, and that will likely balance the effect and keep the number of in total, relatively constant.”

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 2. in MY
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

Malaysia Malaysia Latest News, Malaysia Malaysia Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Our biggest healthcare company says it isn’t scared of OzempicCSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Source: theage - 🏆 8. / 77 Read more »

Our biggest healthcare company says it isn’t scared of OzempicCSL has outlined its growth strategy to investors and played down concerns about weight-loss drugs’ impact on some of its key products.
Source: brisbanetimes - 🏆 13. / 67 Read more »